# INS1201 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ins1201

> INS1201, sponsored by INSMED Inc (INSM): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | INS1201 |
| Codes | INS1201 |
| Sponsor | INSMED Inc (INSM) https://sec-api.dev/companies/insm/catalysts |
| Indications | [pulmonary hypertension associated with interstitial lung disease](https://sec-api.dev/indications/pulmonary-hypertension-associated-with-interstitial-lung-disease), newly diagnosed or recurrent mycobacterium avium complex, pah in early 2026, [duchenne muscular dystrophy](https://sec-api.dev/indications/duchenne-muscular-dystrophy), pah completed, pah completed in december 2024 |
| Modality |  |
| FDA designations | orphan |

## Timeline

### mid-2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: PAH Completed in December 2024.
- First seen 2025-01-10, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "—Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "The Company remains on track to report topline results by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "Topline data continue to be expected before the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm

### Jun 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: PAH Completed.
- First seen 2025-02-20, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Insmed reported positive topline data from the Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) in June 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-031502): "The model was applied to log-transformed PVR values, which were then back-transformed to the original scale; statistically significant, p<0.001; Measurements were taken at ~24 hours post dose ("at trough"); Topline results presented June 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "—Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "Insmed completed the Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), with topline data anticipated in June of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "We anticipate topline results for this study in June 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- SEC Form 10-K (accession 0001104506-25-000009): "We anticipate topline results for this study in mid-2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "Phase 2b PAH Trial Topline Readout Expected in June 2025 PAH Key Trial" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-2.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "Enrollment in the Phase 2b study of TPIP in PAH completed in the fourth quarter of 2024 and we anticipate topline results in June 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- SEC Form 10-K (accession 0001104506-25-000009): "Enrollment in the Phase 2b study of TPIP in PAH completed in the fourth quarter of 2024 and we anticipate topline results in mid-2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm

### Jul 2025: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: Duchenne muscular dystrophy.
- First seen 2025-08-07, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Insmed dosed the first patient in the Phase 1 ASCEND clinical study of INS1201, an intrathecally-delivered gene therapy for patients with Duchenne muscular dystrophy (DMD), in July 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm

### August 12, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-02-06, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "Drug User Fee Act (PDUFA) target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "Fee Act (PDUFA) target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- SEC Form 8-K (accession 0001140361-25-005570): "The FDA previously granted the Company's request for priority review and set a target action date of August 12, 2025 under the Prescription Drug User Fee Act." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_8k.htm
- SEC Form 8-K (accession 0001140361-25-003266): "The FDA has granted the Company's request for priority review and set a target action date of August 12, 2025 under the Prescription Drug" https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-003266): "In its Day 60 communication to Insmed, the FDA granted Priority Review to the NDA and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act (PDUFA)." https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_ex99-1.htm

### early 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3. Indication: PAH in early 2026.
- First seen 2025-01-10, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "The Company plans to initiate a Phase 3 study of TPIP in patients with PAH in early 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Analysis performed using a rank ANCOVA model, adjusting for treatment group, baseline 6-minute walk distance (6MWD), and randomization stratification factors PAH 35% PVR reduction represents largest treatment effect in a well-controlled trial* 35.5m 6MWD improvement achieves a p-value of <0.05** Results reinforce promise of TPIP as the potential prostanoid of choice Expect to initiate Phase 3 trial in early 2026 PH-ILD Expect to initiate Phase 3 trial in 2H:25 Phase" https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "The Company anticipates initiating a Phase 3 study of TPIP in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "The Company plans to initiate a Phase 3 study of TPIP in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "The Company plans to initiate a Phase 3 study of TPIP in patients with PH-ILD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "The Company plans to initiate a Phase 3 study in PH-ILD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled.
- First seen 2025-01-10, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "The Company continues to anticipate a topline readout for ENCORE in the first quarter of 2026, with the submission of a supplementary new drug application (sNDA) to the FDA for ARIKAYCE in all patients with MAC lung disease in the U.S. expected later in 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "The Company continues to anticipate a topline readout for ENCORE in the first quarter of 2026, with the submission of a supplementary new drug application (sNDA) for ARIKAYCE in all patients with MAC lung disease projected for later in 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "—Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "The Company anticipates the topline readout of the Phase 3 ENCORE trial in the first half of 2026 in patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease who have not started antibiotics." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm

## Same indication

- [Deramiocel](https://sec-api.dev/pdufa/deramiocel) (CAPR)
- [Vasculan® (ifetroban)](https://sec-api.dev/pdufa/ifetroban) (CPIX)
- [Rinvatercept](https://sec-api.dev/pdufa/rinvatercept) (KROS)
- [Rostudirsen](https://sec-api.dev/pdufa/rostudirsen) (DYN)
- [SGT-003](https://sec-api.dev/pdufa/sgt-003) (SLDB)
- [SirolimusEFR (sirolimus)](https://sec-api.dev/pdufa/sirolimus) (IRLA)

Calendar months: [August 2025](https://sec-api.dev/fda-calendar/2025-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ins1201.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INS1201 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ins1201

```bibtex
@misc{secapidev_pdufa_ins1201_20261116,
  title        = {INS1201 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ins1201}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ins1201_20261116","title":"INS1201 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ins1201","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
